Clinical Trial

An Interventional Study of Infigratinib in Children With Hypochondroplasia

Study acronym: HCH
Enrolling by Invitation Phase 2/3
View on ClinicalTrials.gov →
Summary
ACCEL2/3 is a Phase 2/3 study. The purpose of the Phase 2 portion of the study (ACCEL2/3) is to evaluate the efficacy and safety of infigratinib in children with hypochondroplasia (HCH) receiving infigratinib at one of two doses, who have completed at least 26 weeks of participation in QED-sponsored ACCEL (QBGJ398-004).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-03-06; most recent amendment 2026-07-14.
Trial Details
NCT Number NCT06873035
Lead Sponsor QED Therapeutics, a BridgeBio company
Conditions Hypochondroplasia
Enrollment 24 participants
Start Date 2025-04-22
Primary Completion 2027-01 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-16